Aldo Ferreira-Hermosillo, Rodolfo Rivas-Ruiz, Ivonne Analí Roy-García, Eduardo Antonio Ferat-Osorio, Octavio Castro-Escamilla, Keiko Taniguchi-Ponciano, Daniel Marrero-Rodríguez, Amelia Irene Rodríguez-Jiménez, Patricia Pérez-Zataray, Jose Luis Cevallos-Rivera, Jorge A Hernández-Casildo, José Félix Saavedra-Ramírez, Víctor G Cruz-Morales, Omar Livio Peralta-Méndez, Alejandro M Vargas-García, Asa Christina Laurell, Rosana Pelayo, Laura C Bonifaz
{"title":"Comprehensive study of associated factors with Type 2 Diabetes in Mexico: protocol.","authors":"Aldo Ferreira-Hermosillo, Rodolfo Rivas-Ruiz, Ivonne Analí Roy-García, Eduardo Antonio Ferat-Osorio, Octavio Castro-Escamilla, Keiko Taniguchi-Ponciano, Daniel Marrero-Rodríguez, Amelia Irene Rodríguez-Jiménez, Patricia Pérez-Zataray, Jose Luis Cevallos-Rivera, Jorge A Hernández-Casildo, José Félix Saavedra-Ramírez, Víctor G Cruz-Morales, Omar Livio Peralta-Méndez, Alejandro M Vargas-García, Asa Christina Laurell, Rosana Pelayo, Laura C Bonifaz","doi":"10.5281/zenodo.15644323","DOIUrl":null,"url":null,"abstract":"<p><p>One of the main goals in the treatment of patients with type 2 diabetes (T2D) is the prevention of its complications. Most existing studies have evaluated a limited and isolated number of inflammatory molecules and metabolic factors, and only rarely have clinical and lifestyle variables been jointly considered. The objective of this study is to describe the protocol design for a comprehensive assessment of patients with T2D, considering glycemic control and the development of complications. A cross-sectional, observational, and multicenter study was conducted in three primary care units located in the states of Coahuila, Jalisco, and Veracruz. Glycemic dysregulation will be assessed by measuring glycated hemoglobin, while diabetic nephropathy will be identified through alterations in the glomerular filtration rate. Additionally, clinical and biochemical parameters, lifestyle habits, physical condition, type of treatment, treatment adherence, and nutritional aspects will be evaluated. Furthermore, transcriptomic analysis using RNA-Seq will be performed to identify the genes that best stratify and distinguish patients with glycemic dysregulation, metabolic alterations, and diabetic nephropathy through principal component analysis and ROC curves based on relative RNA expression. To determine clinical factors associated with the link between molecular profiles and glycemic dysregulation, multiple logistic regression models will be developed to identify a pathological molecular signature characteristic of the disease.</p>","PeriodicalId":94200,"journal":{"name":"Revista medica del Instituto Mexicano del Seguro Social","volume":"63 4","pages":"e6386"},"PeriodicalIF":0.0000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12303611/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista medica del Instituto Mexicano del Seguro Social","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5281/zenodo.15644323","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
One of the main goals in the treatment of patients with type 2 diabetes (T2D) is the prevention of its complications. Most existing studies have evaluated a limited and isolated number of inflammatory molecules and metabolic factors, and only rarely have clinical and lifestyle variables been jointly considered. The objective of this study is to describe the protocol design for a comprehensive assessment of patients with T2D, considering glycemic control and the development of complications. A cross-sectional, observational, and multicenter study was conducted in three primary care units located in the states of Coahuila, Jalisco, and Veracruz. Glycemic dysregulation will be assessed by measuring glycated hemoglobin, while diabetic nephropathy will be identified through alterations in the glomerular filtration rate. Additionally, clinical and biochemical parameters, lifestyle habits, physical condition, type of treatment, treatment adherence, and nutritional aspects will be evaluated. Furthermore, transcriptomic analysis using RNA-Seq will be performed to identify the genes that best stratify and distinguish patients with glycemic dysregulation, metabolic alterations, and diabetic nephropathy through principal component analysis and ROC curves based on relative RNA expression. To determine clinical factors associated with the link between molecular profiles and glycemic dysregulation, multiple logistic regression models will be developed to identify a pathological molecular signature characteristic of the disease.